Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Indian pharma market isn’t going to be that rosy
The Hindu, India
Sunday, September 29, 2013 - 3:19pm
tags:
India
Drug, public interest groups split on compounding bill
The Hill
Sunday, September 29, 2013 - 3:17pm
tags:
compounding pharmacies
Hagens Berman: U.S. Judge Rejects Pharmaceutical Companies' Attempt to Dismiss Thalidomide Cases
Daily Finance
Sunday, September 29, 2013 - 3:16pm
tags:
thalidomide, GSK, Sanofi
Yervoy Battles Melanoma, but Can It Become a Blockbuster?
Motley Fool
Sunday, September 29, 2013 - 1:57pm
tags:
Yervoy, melanoma, Bristol-Myers Squibb
Why This Health Care Giant Can Be a Core Holding
Motley Fool
Sunday, September 29, 2013 - 1:56pm
tags:
JNJ
Meth-Deterring Pseudoephedrine Product, Nexafed, Bioequivalent to Sudafed
Forbes
Sunday, September 29, 2013 - 1:56pm
tags:
Nexafed, Acura Pharmaceuticals, pseudoephedrine
1 Biotech Investment for Every Type of Investor
Motley Fool
Sunday, September 29, 2013 - 1:55pm
tags:
Ligand Pharmaceuticals
Roche immunotherapy drug may be "game changer" in lung cancer
Yahoo/Reuters
Sunday, September 29, 2013 - 1:50pm
tags:
Roche, lung cancer, MPDL3280A
A Reshuffle in a $27 Billion Market
Motley Fool
Sunday, September 29, 2013 - 1:48pm
tags:
COPD, Breo Ellipta, Theravance, GSK
Can Drug-Stock Dividends Last?
Motley Fool
Sunday, September 29, 2013 - 1:47pm
tags:
Time to Panic About Merck's Patent Expirations?
Motley Fool
Sunday, September 29, 2013 - 1:47pm
tags:
Merck, patents
2 Are Better Than 1: Endocyte Uses Diagnostics To Complements Its Drugs
Seeking Alpha
Sunday, September 29, 2013 - 1:41pm
tags:
Endocyte, diagnostics, EC145, ovarian cancer
Meet the 2 Newest Investments in Cystic Fibrosis
Motley Fool
Sunday, September 29, 2013 - 1:37pm
tags:
cystic fibrosis, Kalydeco, Roche, Vertex Pharmaceuticals
Twitter Trounces Wall St. With Real-Time Take on Achillion Pharma's Hep C News
The Street
Sunday, September 29, 2013 - 1:36pm
tags:
twitter, Achillion, hepatitis C
TESARO Describes Initial Phase 1 Clinical Data for TSR-011 Presented at the European Cancer Congress 2013
Yahoo/GlobeNewsWire
Sunday, September 29, 2013 - 1:35pm
tags:
TSR-011, pancreatic cancer, Tesaro
2 More Bold Speculative Biotech Plays
Seeking Alpha
Sunday, September 29, 2013 - 1:34pm
tags:
Geron, Navidea Biopharmaceuticals
BioMarin Provides Updated Phase 1/2 Data on BMN 673 in Breast Cancer at the European Cancer Congress 2013
Yahoo/GlobeNewsWire
Sunday, September 29, 2013 - 1:33pm
tags:
BMN 673, breast cancer, Biomarin
OncoMed Pharmaceuticals Presents Updated Phase 1a Data in Advanced Solid Tumor Patients for the First-in-Class WNT-Pathway-Targeting Antibody Vantictumab (OMP-18R5) at the European Cancer Congress 2013
Yahoo/GlobeNewsWire
Sunday, September 29, 2013 - 1:32pm
tags:
vantictumab, OMP-18R5, neuroendocrine tumors, OncoMed, solid tumors
Ongoing Phase I Monotherapy Study of Rucaparib in Patients with Solid Tumors Demonstrates Clinical Activity, Establishes Dose and Schedule
Yahoo/BusinessWire
Sunday, September 29, 2013 - 1:30pm
tags:
Clovis Oncology, ovarian cancer, rucaparib, solid tumors
Insiders Are Selling Gilead Sciences
Seeking Alpha
Sunday, September 29, 2013 - 1:29pm
tags:
Gilead Sciences

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.